Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemostatic Agent Downclassification Should Await Guidance – Panel

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to develop a draft guidance document for absorbable hemostatic agent 510(k) submissions and submit it for panel review before reconsidering downclassification of the devices

You may also be interested in...



Silicone Sheeting Becomes Class I Exempt Effective Sept. 8 – FDA Final Rule

Class I exempt status for silicone sheeting applies to use of the product on intact skin, FDA emphasizes in an 1Aug. 9 final rule

Silicone Sheeting Becomes Class I Exempt Effective Sept. 8 – FDA Final Rule

Class I exempt status for silicone sheeting applies to use of the product on intact skin, FDA emphasizes in an 1Aug. 9 final rule

Absorbable Hemostatic Agent Downclassification Endorsed By Panel

Content review of FDA's planned special controls guidance was instrumental in the General & Plastic Surgery Devices Panel's July 24 recommendation that absorbable hemostatic agents be downclassified from Class III to Class II

Related Content

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel